Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
NICE’s fast-track catapults Skyrizi into market
contested inflammation and immunology indications as well, such as Crohn’s and ulcerative colitis.
Latest news
-
Takeda makes Crohn’s disease case for subcutaneous Entyvio
to compete strongly against well-established ulcerative colitis drugs such as Humira and Johnson &Johnson’s Simponi (golimumab). ... Takeda has already filed the new formulation for ulcerative colitis in the US and Europe.
-
AbbVie’s Skyrizi gets rapid ‘yes’ from NICE
contested inflammation and immunology indications as well, such as Crohn’s and ulcerative colitis.
-
Gilead strikes $5.1bn deal to bolster ties with Galapagos
Filgotinib is however up against some tough competition in the market, from Pfizer’s blockbuster Xeljanz (tofacitinib) – already approved for RA, psoriatic arthritis and ulcerative colitis – as well as AbbVie’s
-
Latecomer Lilly preps its IL-23 drug for Crohn’s disease
Mirikizumab is however already in three phase 3 ulcerative colitis trials that will start generating results next year, and has a chance of being first to market in this indication – although ... Following last year's presentation of positive phase 2
-
Solid Q1 results lift Pfizer as it waits for pipeline boost
Also among the top performers was rheumatoid arthritis drug Xeljanz (tofacitinib), which posted a healthy 30% rise in sales to $423m thanks to new indications in psoriatic arthritis and ulcerative colitis.
More from news
Approximately 20 fully matching, plus 112 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Biosimilars - the same, but different?
The first months of 2015 also saw it approve Remsima and Inflectra for use on the NHS to treat moderately to severely active ulcerative colitis after the failure of conventional therapy.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
Will lead the development of AVX-470 in ulcerative colitis. Former AstraZeneca (AZ) vice president Dr Deborah Hartman has joined Avaxia Biologics as VP research, replacing Dan Tracey who retires. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Cello Health Insight wins EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'
The winning entry focused on exploring the Crohn’s Disease and Ulcerative Colitis patient journeys – mapping the transactional touchpoints and overlaying the emotional experience of patients so that Janssen could gauge
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US. ... The study employs a mixed quantitative/qualitative methodology and is available to purchase alongside our Living with Ulcerative Colitis 2016 5EU report.
-
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report
Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US.
-
Lucid win PMEA Support Agency of the Year 2016
Highly Commended: Excellence in Healthcare Collaboration and Partnerships – The Ulcerative Colitis Endoscopic Index of Severity Online Tool . Jan Steele (Lucid Co-Founder andCOO) commented: “Being recognised for our work at these
More from PMHub
Approximately 4 fully matching, plus 8 partially matching documents found.
Featured jobs
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director – UK Office
-
Excellent salary and benefits
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
